- 01A small molecule: it works as a pill, and the liver enzyme CYP3A4 sets its interactions
Semaglutide and tirzepatide are peptides, short protein chains that stomach acid and gut enzymes break apart, which is why the Wegovy pill needs an empty stomach and an absorption helper. Orforglipron is a small, non-protein molecule: it can be taken with or without food, and about three-quarters of a 0.8 mg dose reached the blood in a bioavailability study 1. The trade-off is how the body clears it. The liver enzyme CYP3A4 breaks orforglipron down, so drugs that slow or speed up that enzyme move its levels: clarithromycin raised them 3.5-fold and carbamazepine cut them by 82% 1. Orforglipron also works in the other direction on some statins, raising simvastatin's active form 2 to 2.5-fold 1. The convenience and the interaction list are one property seen from two sides.
Foundayo is a GLP-1 tablet with no fasting rule: it can be taken with or without food, like any other daily pill 1. The semaglutide tablets, by contrast, need an empty stomach and a wait before eating 5. Orforglipron is a small molecule that switches on the same GLP-1 receptor (the docking point for the gut hormone that signals fullness) as Wegovy and Zepbound. The same chemistry sets its interaction list: the liver enzyme that clears it, CYP3A4, also handles many antibiotics, seizure drugs and other common medicines 1.
| At a glance | Orforglipron (Foundayo) |
|---|---|
| Drug class | GLP-1 receptor agonist, non-peptide small molecule (code name LY3502970) |
| Maker | Eli Lilly and Company |
| Form | Tablets: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg 1 |
| US approved use | Weight reduction and long-term maintenance in adults with obesity, or overweight with at least one weight-related condition 1 |
| Half-life (time for half a dose to leave the body) | About 29 to 49 hours; steady levels after about a week of daily doses 1 |
| Boxed warning | Thyroid C-cell tumors (C-cells make the hormone calcitonin); a class warning 1 |
| Status, November 2026 | Prescription only in the US; authorized in the UK by the MHRA on 10 August 2026 for weight management and type 2 diabetes 11 |
What orforglipron is, and why a pill matters
GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after a meal. It tells the pancreas to release insulin when blood sugar is high, slows the stomach, and quiets appetite in the brain, which is what people mean when they say these drugs turn down food noise. Drugs that switch on its receptor are called GLP-1 receptor agonists. Orforglipron mimics the hormone's signal; the GLP-1 blood test measures your own hormone and plays no part in dosing the drug.
The earlier GLP-1 drugs are peptides, so they are injected weekly or, for oral semaglutide, taken on an empty stomach with a small sip of water and an absorption enhancer. Orforglipron needs neither, because it is a non-peptide molecule that survives the gut. The ACHIEVE-3 investigators put the design goal this way:
Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions.Rosenstock J et al., ACHIEVE-3, The Lancet, 2026 5
| Peptide pill (Wegovy pill, Rybelsus) | Small-molecule pill (Foundayo) | |
|---|---|---|
| What the drug is | Semaglutide, a peptide | Orforglipron, a non-peptide molecule |
| Food and water | Empty stomach, timed water and a wait before eating; see the semaglutide guide | With or without food 1 |
| How much reaches the blood | Low, which is why it needs an absorption enhancer | 77% of a 0.8 mg dose 1 |
| How the body clears it | Broken down like other proteins | Liver enzyme CYP3A4 1 |
| Interaction focus | Mostly slower stomach emptying | Slower stomach emptying plus CYP3A4 drugs and some statins 1 |
Foundayo doses: the trial numbers vs the tablets you get
The phase 3 trials used an investigational formulation dosed at 6, 12 and 36 mg, and the published trial reports use those numbers 2. The Foundayo label reports the same trial arms as equivalent doses of the commercial tablet: 5.5, 9 and 17.2 mg 1 2. A news story about orforglipron 36 mg is describing the 17.2 mg Foundayo tablet; the ACHIEVE-4 report states the equivalence outright 7.
| Dose in the trial papers | Equivalent Foundayo tablet |
|---|---|
| 6 mg | 5.5 mg |
| 12 mg | 9 mg |
| 36 mg | 17.2 mg |
- 1Month 1: 0.8 mgThe starting tablet. The label's slow climb exists to keep stomach side effects down 1.
- 2Month 2: 2.5 mgAfter at least 30 days on 0.8 mg 1.
- 3Month 3: 5.5 mgAfter at least 30 days on 2.5 mg. This is the lowest of the three doses tested in the weight-loss trials 1.
- 4Month 4 onward: 9, 14.5 or 17.2 mgThe prescriber can move up one step at a time, at least 30 days apart, based on response and side effects. The maximum is 17.2 mg a day 1.
If a tablet is missed, the label says to take it as soon as you remember and never double the next dose; after 7 or more missed days in a row, the climb restarts at a lower dose to avoid a burst of nausea 1. The prescriber sets the dose and the pace of each step.
Taking Foundayo tablets
How much weight do people lose on orforglipron?
Two 72-week placebo-controlled trials, labelled Trial 1 and Trial 2 in the prescribing information, support the approval. Trial 1 (ATTAIN-1) enrolled 3,127 adults without diabetes; Trial 2 (ATTAIN-2) enrolled 1,613 adults with type 2 diabetes 1 2 3. Everyone, placebo groups included, got diet and activity counselling, so the placebo numbers show what lifestyle advice alone did.
| Week 72 result | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Trial 1, no diabetes: average weight change | -2.1% | -7.4% | -8.3% | -11.1% |
| Trial 1: lost at least 10% | 13% | 32.5% | 39.8% | 54.5% |
| Trial 1: lost at least 15% | 6% | 14.3% | 20.1% | 35.9% |
| Trial 1: lost at least 20% | 2.9% | 5.9% | 8.9% | 18.4% |
| Trial 2, type 2 diabetes: average weight change | -2.5% | -5.1% | -7.0% | -9.6% |
| Trial 2: lost at least 10% | 9.2% | 22.5% | 31.1% | 45.6% |
The figures are from the Foundayo label 1; the ATTAIN-1 paper reports the same trial with slightly different rounding (-11.2% at 36 mg) 2. The spread matters as much as the average. At 17.2 mg in Trial 1, more than half of people lost 10% or more and nearly one in five lost 20% or more, while others lost little 1. For a person starting at 100 kg (220 lb), the top-dose average works out to about 11 kg (24 lb), against about 2 kg on placebo. People with type 2 diabetes lost less: 9.6% at the top dose in Trial 2 against 11.1% in Trial 1 1.
Trial 1 also tracked other heart-risk measures. Waist size fell 10 cm at the top dose against 3.1 cm on placebo, and systolic blood pressure, triglycerides and non-HDL cholesterol improved more than on placebo 1 2.
Blood sugar and heart: the diabetes trials
In Trial 2, people with type 2 diabetes started with an average HbA1c of 8.0%. HbA1c, the share of hemoglobin carrying glucose, reflects average blood sugar over about three months. It fell by 1.2, 1.4 and 1.7 percentage points on the three doses, against 0.4 on placebo 1. In ACHIEVE-1, 559 adults with early type 2 diabetes managed by diet and exercise alone took orforglipron or placebo for 40 weeks; HbA1c fell 1.24 to 1.48 points from 8.0%, against 0.41 on placebo, with no severe low blood sugar 4. The A1C calculator turns an HbA1c into an average glucose.
ACHIEVE-3, a head-to-head trial against the semaglutide tablet, gave 1,698 adults on metformin orforglipron or oral semaglutide for 52 weeks, starting from an average HbA1c of 8.3% 5. Orforglipron lowered HbA1c more, but it also caused more stopping and a larger rise in pulse 5:
| ACHIEVE-3 arm (trial dose) | HbA1c fall | Stopped for side effects | Pulse rise |
|---|---|---|---|
| Orforglipron 12 mg | 1.71 points | 9% | 3.7 beats a minute |
| Orforglipron 36 mg (the 17.2 mg tablet) | 1.91 points | 10% | 4.7 beats a minute |
| Oral semaglutide 7 mg | 1.23 points | 4% | 1.0 beat a minute |
| Oral semaglutide 14 mg | 1.47 points | 5% | 1.5 beats a minute |
ACHIEVE-4 tested heart safety in 2,749 adults with type 2 diabetes and established heart or kidney disease. Over a median of 2 years, major cardiovascular events (heart-related death, heart attack, stroke, or a hospital stay for unstable angina, which is chest pain from a narrowing heart artery) occurred in 4.2% on orforglipron and 5.0% on insulin glargine, a long-acting daily insulin 7. ACHIEVE-4 met its goal of showing orforglipron was no worse than insulin glargine for heart risk. It shows safety, not heart protection.
Orforglipron vs Wegovy, the Wegovy pill and Zepbound
| Foundayo (orforglipron) | Wegovy pill (oral semaglutide) | Wegovy (semaglutide injection) | Zepbound (tirzepatide injection) | |
|---|---|---|---|---|
| How taken | Tablet, daily | Tablet, daily | Injection, weekly | Injection, weekly |
| Receptors | GLP-1 | GLP-1 | GLP-1 | GLP-1 and GIP (a second gut hormone) |
| Food rule | None 1 | Empty stomach | None | None |
| Average loss at top dose, own main trial | 11.1% at 72 weeks 1 | 13.6% at 64 weeks (OASIS 4) 9 | 14.9% at 68 weeks (STEP 1) 8 | 20.9% at 72 weeks (SURMOUNT-1) 10 |
The weight figures in this table come from separate trials with different people, lengths and methods, so treat the gaps between them as rough. On weight alone, orforglipron sits below the other three. ACHIEVE-3, the head-to-head trial with oral semaglutide, was run in type 2 diabetes with blood sugar as its main measure, not weight loss in obesity 5. Retatrutide, a weekly triple-receptor injection still in trials, is set against semaglutide in retatrutide vs semaglutide, and cagrilintide is another weight drug in development.
For people already on an injection, the relevant trial is ATTAIN-MAINTAIN. Adults who had reached a weight plateau on tirzepatide or semaglutide switched to orforglipron or placebo for 52 weeks. Those switched from tirzepatide kept 74.7% of their earlier weight loss on orforglipron versus 49.2% on placebo; those switched from semaglutide kept 79.3% versus 37.6% 6. The trial had no group that stayed on the injection, so it cannot say whether switching holds weight as well as continuing 6. Whether to switch, continue or stop is a decision to make with the prescriber.
Side effects, and how often they happen
| Side effect (Trials 1 and 2 pooled) | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Indigestion | 4% | 12% | 16% | 13% |
| Belly pain | 7% | 13% | 14% | 14% |
| Bloating | 3% | 7% | 9% | 8% |
| Headache | 7% | 8% | 9% | 9% |
| Fatigue | 4% | 6% | 7% | 9% |
| Burping | 1% | 6% | 8% | 8% |
| Reflux | 2% | 6% | 6% | 7% |
| Gas | 2% | 5% | 6% | 6% |
| Hair loss | 2% | 4% | 4% | 5% |
| Stopped the drug because of side effects | 3% | 6% | 9% | 10% |
Any stomach side effect affected 60% to 69% of people on Foundayo against 37% on placebo, and most cases were mild or moderate 1. Nausea, vomiting and diarrhea peaked during the dose climb and eased over time 1. Hair loss tracked weight loss and was more common in women: 7% of women on Foundayo against 0.9% of men on Foundayo 1. Less common effects in the pooled trials included gallstones (1% vs 0.7%), low blood pressure (2% vs 0.5%, and 4% in people already on blood pressure tablets), and a fast heart rate (3% vs 0.9%) 1.
What can change on your blood tests
Foundayo moves several common lab results. Some flags on a report during treatment match the drug's known average effects, but only your prescriber can say whether a given result is that or something else, and trial averages do not show what is normal for one person. Show any flagged result to them rather than assuming. Lipase and amylase, two pancreas enzymes, rose by 26% to 31% and 16% to 20% on average, against 4% and 3% on placebo 1. The label is plain about what that rise means on its own:
The clinical significance of elevations in amylase or lipase with FOUNDAYO is unknown in the absence of other signs and symptoms of pancreatitis.
If your lipase or amylase comes back flagged and you feel well, do not stop the tablet on your own: send the result to your prescriber, who may repeat it. If you have severe belly pain that will not settle, get same-day care whatever the number.
| Marker | What happened in the trials | When it matters |
|---|---|---|
| Lipase | Up 26% to 31% on average 1 | A high lipase on its own still goes to the prescriber; with severe, lasting belly pain, same-day care whatever the number |
| Amylase | Up 16% to 20% on average 1 | Same as lipase |
| HbA1c | Down 1.2 to 1.7 points from 8.0% with diabetes; barely moved from an average of 5.6% without 1 | With diabetic eye disease, a fast fall can temporarily worsen retinopathy (diabetes damage to the back of the eye), so the label asks for monitoring 1. An A1c of 5.7% to 6.4% falls in the prediabetes range |
| Fasting glucose | Readings under 54 mg/dL in 2% with type 2 diabetes vs 0.2% on placebo, and 0.6% vs none without diabetes 1 | On insulin or a sulfonylurea, report low readings or low-sugar symptoms to the prescriber, who may lower those doses 1 |
| Triglycerides | Down about 10% to 20% from baseline, against about 4% on placebo 1 | Discuss any flagged result with your prescriber |
| HDL cholesterol | Up 2% to 8% from baseline across the trials 1 | Discuss any flagged result with your prescriber |
| LDL cholesterol | Down 3.8% to 5.5% from baseline in Trial 1, vs 1.6% on placebo 1 | Too small a change to replace a cholesterol medicine; see how to read your lipid panel |
| Creatinine and eGFR | No direct effect; acute kidney injury in 0.2% vs 0.05% 1 | A creatinine rise after days of vomiting or diarrhea; see kidney function explained |
| Heart rate | Up 4 to 5 beats per minute on average, vs 0.5 on placebo 1 | A resting pulse that stays fast, or palpitations |
Markers to read beside Foundayo
Two practical points follow. First, ask your clinician whether to draw a baseline panel before the first tablet (HbA1c, a lipid panel, lipase, and creatinine with eGFR) and when to recheck once you are on a steady dose, so later numbers have something to be read against (see why trends beat single readings). Second, the label does not ask for calcitonin or thyroid scans: it calls routine monitoring of serum calcitonin or thyroid ultrasound "of uncertain value" for catching medullary thyroid cancer early 1.
Medicines that interact with Foundayo
| Medicine | What happens | What the label says |
|---|---|---|
| Birth control pills | Slower stomach emptying may reduce how much of the pill is absorbed | Switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase; non-oral hormonal methods should not be affected 1 |
| Strong CYP3A4 inhibitors (drugs that slow the enzyme), such as the antibiotic clarithromycin | Orforglipron levels rose 3.5-fold with clarithromycin 1 | Top Foundayo dose of 9 mg; avoid ones that also block a second clearance route, such as the HIV booster ritonavir 1 |
| Strong CYP3A4 inducers (drugs that speed the enzyme up), such as the seizure drug carbamazepine | Orforglipron levels fell 82% 1 | Avoid; with moderate ones, such as the HIV medicine efavirenz, the prescriber watches the effect 1 |
| Simvastatin | Active simvastatin rose 2 to 2.5-fold 1 | Do not exceed 20 mg of simvastatin a day 1 |
| Atorvastatin and rosuvastatin | Levels rose 1.5-fold and 1.7-fold 1 | No dose limit listed |
| Insulin or sulfonylureas | Low blood sugar: 7% on a sulfonylurea vs 0.5% without, in Trial 2 1 | The prescriber may lower the insulin or sulfonylurea dose 1 |
| Another GLP-1 drug | Two drugs acting on the same receptor | Not recommended together 1 |
| Other oral medicines | Absorbed more slowly, most after the first dose 1 | Ask the prescriber or pharmacist about drugs where timing matters |
Our statins page covers the wider statin family. The birth control rule is about the stomach emptying more slowly, which is why it applies again after each dose step; our guide to birth control and blood tests covers the other lab effects of the pill.
Who it is for, and who should not take it
The US label covers adults with obesity, or overweight with at least one weight-related condition. In the trials that meant a BMI of 30 or more, or 27 to 30 with a condition such as high blood pressure, high cholesterol, sleep apnea or heart disease 1. Whether it suits you is a decision for a prescriber. BMI misses where fat sits, so a waist-to-height ratio is a useful second number.
CalculatorBMI calculatorWorks out the BMI the Foundayo trials used to decide who could take partWork it out - Do not take it with a personal or family history of medullary thyroid cancer or MEN 2, or after a serious allergic reaction to orforglipron 1.
- Not recommended with severe gastroparesis (a stomach that already empties very slowly), severe liver disease or while breastfeeding 1.
- Tell the prescriber about any past pancreatitis or gallbladder disease; both are warnings on the label 1.
- Pregnancy: the label says to stop once pregnancy is recognized, and advises effective contraception during treatment 1.
- Not established in under-18s 1.
- Kidney disease, including chronic kidney disease, needs no dose change; kidney function is watched if vomiting or diarrhea set in 1.
- Before surgery or sedation, tell the team you take it: food can stay in a slowed stomach 1.
Human trials vs preclinical data
Everything above comes from human trials. The preclinical studies could not test the usual thyroid question, because orforglipron does not act on the GLP-1 receptor in the species those studies use; the standard preclinical cancer studies found no tumors but could not have shown the class effect 1. The label keeps the GLP-1 boxed thyroid warning and says the human relevance is unknown 1. Pregnancy studies in monkeys, where the drug is active, could only test doses below human exposure 1.
Stopping, muscle and keeping the weight off
The label reports that Foundayo removes more fat than lean mass, but some of the weight lost is muscle 1. Ask the prescriber or a dietitian about protein and strength training to protect muscle while the weight comes off; the lean body mass calculator gives a starting estimate.
CalculatorProtein calculatorTurns your body weight into a daily protein range when appetite is smallWork it out Weight tends to come back when a GLP-1 drug stops. In ATTAIN-MAINTAIN, people switched to placebo after an injection kept only 38% to 49% of their loss over a year 6. A plan to stop or pause is worth talking through with the prescriber first. Our weight-loss hub puts these drugs beside the other levers.
Cost, legal status and how to get it
| Foundayo dose | LillyDirect self-pay price, as of November 2026 12 |
|---|---|
| 0.8 mg | From $149 a month |
| 2.5 mg | From $149 a month (temporarily reduced through 31 December 2026) |
| 5.5 mg | From $199 a month (temporarily reduced through 31 December 2026) |
| 9 mg | From $299 a month |
| 14.5 mg | From $299 a month when refilled within 45 days |
| 17.2 mg | From $299 a month when refilled within 45 days |
Foundayo is prescription only. Lilly lists the prices above on LillyDirect, says people with commercial insurance that covers Foundayo could pay as little as $25 a month with its savings card, and points eligible Medicare Part D patients prescribed it for weight to a Medicare GLP-1 Bridge program 12. Prices change, so check the current page. In the UK it is not currently available on the NHS, and NHS use depends on an evaluation by NICE 11.
Free, no accountRead your blood testHave a panel from before or during Foundayo? Read your lipase, A1c, lipids and kidney numbers line by line, free.Read my results
Citations
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use: US prescribing information. Revised 07/2026.
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806.
- Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944.
- Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med. 2025;393(11):1065-1076.
- Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147-1160.
- Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687.
- Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026;408(10564):1557-1570.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK, 10 August 2026.
- Eli Lilly and Company. Foundayo on LillyDirect: self-pay prices and savings. Accessed 21 November 2026.
- US Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher program (Foundayo). FDA press announcement, 1 April 2026.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.





